Abstract
In 1982 the macrocyclic lactone, ivermectin, was first tested in human patients with onchocerciasis. It has since undergone phase I to IV trials and is now being widely distributed in onchocercal areas. The previous microfilaricide, diethylcarbamazine citrate (DEC), is known to precipitate or exacerbate active optic neuritis in some onchocercal patients, as part of a wider inflammatory response (the Mazzotti reaction). Ivermectin may also cause a mild reaction, especially in people with high microfilarial loads. Few data are available concerning the effect of ivermectin on active optic neuritis. A large, randomised, double-masked, phase IV trial is reported. Individuals were screened for evidence of optic nerve disease (OND), and those identified as possible cases of OND underwent detailed ophthalmic examination, including fluorescein angiography, before being dosed with ivermectin or placebo. A total of 6831 persons were screened of whom 856 (13%) underwent angiography prior to dosing. At 7-14 days after dosing an attempt was made to reexamine 50% of adults over the age of 20 years, including all those with OND. Six hundred and eighty-eight repeat or new angiograms were performed. During this period, 5 new cases of active optic neuritis and one case of exacerbation of existing optic neuritis were identified. Five of these individuals had received placebo and one ivermectin. Two individuals with optic neuritis before dosing had improved after 7-14 days. One had received placebo, the other ivermectin. Ivermectin does not appear to precipitate or exacerbate optic neuritis at a period of 7-14 days.
Similar content being viewed by others
Article PDF
References
WHO Expert Committee on Onchocerciasis. Third report. WHO Technical Report Series no. 752, 1987.
Prost A . The burden of blindness in adult males in the savannah villages of West Africa exposed to onchocerciasis. Trans R Soc Trop Med Hyg 1986; 80: 525–7.
Mazzotti L . Presencia de microfilarias de Onchocerca volvulus en el liquido cefalorraquideo de enfermos tratados con hetrazan. Rev Inst Salubr Enferm Trop (Mex) 1959; 19: 1–5.
Anderson J, Fuglsang H, Marshal TF de C . Effects of diethylcarbamazine on ocular onchocerciasis. Tropenmed Parasitol 1976; 27: 263–78.
Anderson J, Fuglsang H . Further studies on the treatment of ocular onchocerciasis with diethylcarbamazine and suramin. Br J Ophthalmol 1978; 62: 450–7.
Bird AC, Hadi El Sheikh, Anderson J, Fuglsang H . Changes in visual function and in the posterior segment of the eye during therapy of onchocerciasis with diethylcarbamazine citrate. Br J Ophthalmol 1980; 64: 191–200.
Aziz MA, Diallo S, Diop IM, Lariviere M, Porta M . Efficacy and tolerance of ivermectin in human onchocerciasis. Lancet 1982; 2: 171–3.
Prod'hon J, Boussinesq M, Fobi G, Prud'hom JM, Enyong P, Lafleur C, Quillevere D . Lutte contre l'onchocercose par ivermectine: resultats d'une campagne de masse au Nord-Cameroun. Bull Organ Mondiale Sante 1991; 69: 443–50.
Dadzie KY, Awadzi K, Bird AC, Schulz-Key H . Ophthalmological results from a placebo controlled comparative 3-dose ivermectin study in the treatment of onchocerciasis. Trop Med Parasitol 1989; 40: 355–60.
Abiose A, Murdoch I, Babalola O, Cousens S, Liman I, Onyema J, Jones B . The distribution and aetiology of blindness and visual impairment in mesoendemic onchocercal communities, Kaduna State, Nigeria. Br J Ophthalmol (in press).
Anderson J, Fuglesang H, Hamilton PJS, Marshall TF de C . Studies on onchocerciasis in the United Cameroon Republic. I. Comparison of populations with and without Onchocerca volvulus. Trans R Soc Trop Med Hyg 1974; 68: 190–208.
Anderson J, Fuglsang H, Marchall TF de C . Studies on onchoceriasis in the United Cameroon Republic. III. A four year follow-up of 6 rain-forest and 6 Sudan-savannah villages. Trans R Soc Trop Med Hyg 1976; 70: 362–73.
McMahon JE, Sowa SCI, Maude GYH, Hudson CM, Kirk-wood BR . Epidemiological studies of onchocerciasis in forest villages of Sierra Leone. Trop Med Parasitol 1988; 39: 251–9.
Abiose A, Jones B, Cousens S, Murdoch I, Cassels-Brown A, Babalola O, Alexander N, et al. A randomised, controlled trial of ivermectin for onchocerciasis: evidence for a reduction in incidence of optic nerve disease. Lancet 1993; 1: 130–4.
Newland HR, White AT, Greene BM, D'Anna S, Keyvan-Larijani E, Aziz MA, et al. Effect of single-dose ivermectin therapy on human Onchocerca volvulus infection with onchocercal ocular involvement. Br J Ophthalmol 1988; 72: 561–9.
Rothova A, Van der Lelij A, Stilma JS, Klassen-Broekema N, Wilson WR, Barbe RF . Ocular involvement in patients with onchocerciasis after repeated treatment with ivermectin. Am J Ophthalmol 1990; 110: 6–16.
Dadzie KY, Bird AC, Awadzi K, Schulz-Key H, Gilles HM, Aziz MA . Ocular findings in a double-blind study of ivermectin versus diethylcarbamazine versus placebo in the treatment on onchocerciasis. Br J Ophthalmol 1987; 71: 78–85.
Greene BM, Taylor HR, Cupp EW, Murphy RP, White AT, Aziz MA, et al. Comparison of ivermectin and diethylcarbamazine in the treatment of onchocerciasis. N Engl J Med 1985; 313: 133–8.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Murdoch, I., Abiose, A., Babalola, O. et al. Ivermectin and onchocercal optic neuritis: Short-term effects. Eye 8, 456–461 (1994). https://doi.org/10.1038/eye.1994.108
Issue Date:
DOI: https://doi.org/10.1038/eye.1994.108
Keywords
This article is cited by
-
Onchocerciasis drug development: from preclinical models to humans
Parasitology Research (2021)